Supreme Court exposes GlaxoSmithKline to Humana's Avandia-spending claims

The U.S. Supreme Court declined to consider an appeal from GlaxoSmithKline ($GSK) in a fight over Humana's spending on the company's disgraced diabetes drug Avandia. The ruling not only opens GSK to the Humana suit, which applies to its Medicare Advantage plans, but also to potential lawsuits from other insurers. Report

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.